

**Supplementary Material**

Table S1. Mean and standard error of the genetic risk score (GRS) for T2D among all women with genetic data in the NHSII and DNBC.

Variable	Non-T2D			T2D			<i>P</i> -value <sup>a</sup>
	#	Mean	STD	#	Mean	STD	
NHSII							
GRS	1438	67.65	5.68	446	68.17	6.06	0.10
Pre-pregnancy BMI	504	25.05	5.14	149	31.18	7.15	< 0.001
AHEI after the index pregnancy <sup>b</sup>	894	47.27	10.54	278	45.41	9.91	0.009
DNBC							
GRS	395	67.11	5.56	155	67.82	5.60	0.50
Pre-pregnancy BMI	395	26.15	4.93	155	30.26	6.33	< 0.001
AHEI after the index pregnancy <sup>c</sup>	395	51.94	9.44	155	50.68	9.32	0.14

<sup>a</sup>*P*-values were obtained from t-test between the two groups.

<sup>b</sup>Derived from the earliest dietary assessment after the index pregnancy.

<sup>c</sup>Derived from the dietary assessment at the follow-up clinical exam in DNBC.

Table S2. Candidate single nuclear polymorphisms (SNPs) and their associations with the risk of type 2 diabetes among women who had gestational diabetes in the Nurses' Health Study II (NHSII, N = 1,884) and the Danish National Birth Cohort (DNBC, N = 550).

SNP	BP	Chr	Gene	Func	type 2 diabetes risk allele	Reference allele	Confirmation in Scott et. al., 2017 <sup>1</sup>		Confirmation in Mahajan et. al., 2014 <sup>2</sup>		NHSI			DNBC			Pooled <sup>a</sup>		
							Relevant SNP	R <sup>2</sup>	Relevant SNP	R <sup>2</sup>	EAf	RR (95% CI) <sup>b</sup>	P	EAf	RR (95% CI) <sup>b</sup>	P	RR (95% CI)	P	P, FDR corrected
rs10923931	119975336	1	NOTCH2	-	T	G			rs10923931	Same	0.11	1.03 (0.85, 1.23)	0.79	0.11	0.77 (0.55, 1.07)	0.12	0.96 (0.82, 1.12)	0.59	0.75
rs243021	60357684	2	BCL11A	-	A	G			rs243088	0.88	0.47	0.99 (0.89, 1.11)	0.91	0.49	1.06 (0.87, 1.29)	0.56	1.01 (0.91, 1.12)	0.85	0.88
rs2943641	226229029	2	LOC64673, IRS1	IR	C	T	rs2972156	0.91	rs2943640	0.94	0.65	1.07 (0.95, 1.20)	0.30	0.65	1.10 (0.89, 1.34)	0.38	1.07 (0.97, 1.19)	0.18	0.59
rs3923113	164645339	2	GRB14	IR	A	C			rs3923113	Same	0.64	1.06 (0.94, 1.20)	0.34	0.63	1.19 (0.97, 1.47)	0.10	1.09 (0.98, 1.21)	0.10	0.39
rs7578326	226155937	2	IRS1	IR	A	G					0.66	1.08 (0.96, 1.22)	0.20	0.77	1.06 (0.87, 1.30)	0.56	1.08 (0.97, 1.20)	0.16	0.56
rs7578597	43505684	2	THADA	BC	T	C	rs6757251	0.97	rs10203174	0.91	0.90	1.07 (0.87, 1.31)	0.53	0.92	1.21 (0.83, 1.76)	0.33	1.10 (0.92, 1.32)	0.30	0.65
rs7593730	160314943	2	ITGB6/RBMS1	IR	C	T			rs7593730	Same	0.78	1.06 (0.92, 1.22)	0.43	0.81	0.93 (0.74, 1.17)	0.54	1.02 (0.90, 1.15)	0.73	0.84
rs7607980	164694691	2	COBLL1	-	T	C					0.86	1.10 (0.92, 1.30)	0.29	0.85	1.32 (0.97, 1.79)	0.08	1.15 (0.99, 1.33)	0.07	0.34
rs16861329	186948673	3	ST6GAL1	-	C	T			rs16861329	Same	0.87	1.13 (0.94, 1.36)	0.19	0.87	1.21 (0.91, 1.60)	0.18	1.03 (0.88, 1.20)	0.71	0.84
rs1801282	12351626	3	PPARG	IR	C	G	rs11712037	0.94	rs1801282	Same	0.88	1.00 (0.84, 1.20)	0.96	0.86	1.00 (0.76, 1.31)	0.99	1.00 (0.86, 1.16)	0.97	0.97
rs4402960	185793899	3	IGF2BP2	BC	T	G	rs4402960	Same	rs4402960	Same	0.33	1.07 (0.95, 1.20)	0.29	0.32	1.06 (0.87, 1.30)	0.55	1.07 (0.96, 1.18)	0.22	0.59
rs4607103	64726228	3	ADAMTS9	IR	C	T					0.77	0.94 (0.82, 1.07)	0.34	0.78	0.96 (0.77, 1.19)	0.70	0.94 (0.84, 1.06)	0.31	0.65
<b>rs1801214</b>	<b>6301295</b>	<b>4</b>	<b>WFS1</b>	<b>BC</b>	<b>T</b>	<b>C</b>			<b>rs4458523</b>	<b>0.96</b>	<b>0.60</b>	<b>1.15 (1.02, 1.30)</b>	<b>0.03</b>	<b>0.60</b>	<b>1.02 (0.85, 1.24)</b>	<b>0.81</b>	<b>1.11 (1.00, 1.23)</b>	<b>0.04</b>	<b>0.24</b>
<b>rs4689388</b>	<b>6268329</b>	<b>4</b>	<b>WFS1</b>	<b>BC</b>	<b>A</b>	<b>G</b>			<b>rs4458523</b>	<b>0.85</b>	<b>0.59</b>	<b>1.16 (1.03, 1.31)</b>	<b>0.02</b>	<b>0.58</b>	<b>1.04 (0.86, 1.26)</b>	<b>0.68</b>	<b>1.12 (1.02, 1.25)</b>	<b>0.02</b>	<b>0.24</b>
rs6815464	1316113	4	MAEA	BC	C	G					0.97	1.05 (0.73, 1.51)	0.78	0.98	1.24 (0.72, 2.16)	0.44	0.97 (0.72, 1.31)	0.85	0.88
rs4457053	77129124	5	ZBED3	-	G	A			rs6878122	0.93	0.31	1.06 (0.94, 1.20)	0.37	0.30	1.20 (0.96, 1.50)	0.12	1.00 (0.90, 1.12)	0.97	0.97
rs1535500	39316274	6	KCNK16	-	T	G					0.50	0.95 (0.85, 1.06)	0.37	0.49	1.00 (0.83, 1.20)	0.97	0.96 (0.87, 1.06)	0.44	0.72
rs7754840	20661019	6	CDKAL1	BC	C	G					0.33	0.97 (0.86, 1.10)	0.64	0.37	1.33 (1.10, 1.60)	0.00	1.06 (0.96, 1.18)	0.24	0.62
<b>rs7766070</b>	<b>20686342</b>	<b>6</b>	<b>CDKAL1</b>	<b>BC</b>	<b>A</b>	<b>C</b>	<b>rs7451008</b>	<b>0.97</b>	<b>rs7756992</b>	<b>0.98</b>	<b>0.28</b>	<b>1.05 (0.93, 1.19)</b>	<b>0.45</b>	<b>0.32</b>	<b>1.28 (1.06, 1.54)</b>	<b>0.01</b>	<b>1.11 (1.00, 1.24)</b>	<b>0.04</b>	<b>0.24</b>
<b>rs10229583</b>	<b>127606849</b>	<b>7</b>	<b>ARF5, PAX4, SND1</b>	<b>-</b>	<b>G</b>	<b>A</b>			<b>rs10229583</b>	<b>Same</b>	<b>0.78</b>	<b>1.06 (0.92, 1.23)</b>	<b>0.39</b>	<b>0.77</b>	<b>1.31 (1.04, 1.65)</b>	<b>0.02</b>	<b>1.13 (1.00, 1.27)</b>	<b>0.05</b>	<b>0.27</b>
rs849134	28156603	7	JAZF1	BC	A	G	rs1635852	0.95	rs849135	0.95	0.51	1.04 (0.93, 1.16)	0.53	0.45	0.99 (0.82, 1.20)	0.94	1.03 (0.93, 1.13)	0.62	0.75
rs972283	130782095	7	KLF14	IR	G	A	rs10954284	0.98	rs13233731	0.95	0.54	1.05 (0.93, 1.18)	0.43	0.51	0.97 (0.80, 1.17)	0.74	1.03 (0.93, 1.13)	0.62	0.75
rs13266634	117172544	8	SLC30A8	BC	C	T	rs3802177	Same	rs3802177	Same	0.72	0.96 (0.84, 1.09)	0.51	0.72	1.00 (0.82, 1.22)	1.00	0.97 (0.87, 1.08)	0.57	0.75
rs896854	94948283	8	TP53INP1	-	T	C			rs7845219	0.92	0.49	0.96 (0.86, 1.08)	0.54	0.45	1.07 (0.88, 1.29)	0.52	0.99 (0.90, 1.09)	0.84	0.88
<b>rs10811661</b>	<b>22134095</b>	<b>9</b>	<b>CDKN2A/B</b>	<b>BC</b>	<b>T</b>	<b>C</b>	<b>rs10965248</b>	<b>0.97</b>	<b>rs10811661</b>	<b>Same</b>	<b>0.83</b>	<b>0.90 (0.78, 1.05)</b>	<b>0.19</b>	<b>0.85</b>	<b>0.75 (0.59, 0.95)</b>	<b>0.02</b>	<b>0.86 (0.76, 0.97)</b>	<b>0.02</b>	<b>0.24</b>
<b>rs11787792</b>	<b>136357696</b>	<b>9</b>	<b>GPSM1</b>	<b>-</b>	<b>A</b>	<b>G</b>	<b>rs11787792</b>	<b>Same</b>			<b>0.64</b>	<b>1.18 (1.04, 1.33)</b>	<b>0.01</b>	<b>0.66</b>	<b>0.99 (0.81, 1.22)</b>	<b>0.95</b>	<b>1.12 (1.01, 1.25)</b>	<b>0.03</b>	<b>0.24</b>
rs13292136	79337213	9	CHCHD9	-	C	T					0.94	0.96 (0.76, 1.21)	0.72	0.94	1.47 (0.88, 2.47)	0.15	1.03 (0.83, 1.27)	0.80	0.88

SNP	BP	Chr	Gene	Func	type 2 diabetes risk allele	Reference allele	Confirmation in Scott et al., 2017 <sup>1</sup>		Confirmation in Mahajan et al., 2014 <sup>2</sup>		NHSI			DNBC			Pooled <sup>a</sup>		
							Relevant SNP	R <sup>2</sup>	Relevant SNP	R <sup>2</sup>	EAF	RR (95% CI) <sup>b</sup>	P	EAF	RR (95% CI) <sup>b</sup>	P	RR (95% CI)	P	P, FDR corrected
rs7018475	22137686	9	CDKN2B	BC	T	G					0.73	1.11 (0.97, 1.27)	0.13	0.72	1.09 (0.88, 1.34)	0.42	1.10 (0.99, 1.24)	0.09	0.38
<b>rs7020996</b>	<b>22129580</b>	<b>9</b>	<b>CDKN2A/B</b>	<b>BC</b>	<b>C</b>	<b>T</b>					<b>0.87</b>	<b>0.88 (0.75, 1.03)</b>	<b>0.12</b>	<b>0.89</b>	<b>0.83 (0.64, 1.09)</b>	<b>0.18</b>	<b>0.87 (0.76, 1.00)</b>	<b>0.04</b>	<b>0.24</b>
<b>rs7041847</b>	<b>4287466</b>	<b>9</b>	<b>GLIS3</b>	<b>BC</b>	<b>A</b>	<b>G</b>			<b>rs7041847</b>	<b>Same</b>	<b>0.54</b>	<b>0.91 (0.81, 1.02)</b>	<b>0.10</b>	<b>0.52</b>	<b>0.87 (0.72, 1.04)</b>	<b>0.12</b>	<b>0.89 (0.81, 0.99)</b>	<b>0.03</b>	<b>0.24</b>
rs10906115	12272998	10	CDC123-CAMK1D	BC	A	G					0.61	1.01 (0.90, 1.15)	0.82	0.61	0.89 (0.74, 1.07)	0.22	0.97 (0.88, 1.08)	0.62	0.75
rs1111875	92703125	10	HHEX	BC	C	T			rs1111875	Same	0.61	0.97 (0.86, 1.09)	0.57	0.64	0.87 (0.71, 1.05)	0.15	0.94 (0.85, 1.04)	0.22	0.59
rs11257655	12265895	10	CDC123	BC	T	C	rs11257659	0.94	rs11257655	Same	0.21	0.97 (0.84, 1.12)	0.66	0.77	0.95 (0.76, 1.18)	0.61	0.96 (0.85, 1.08)	0.52	0.75
rs4506565	112996282	10	TCF7L2	BC	T	A	rs7903146	0.92	rs7903146	0.92	0.35	1.08 (0.96, 1.22)	0.21	0.33	0.99 (0.81, 1.20)	0.89	1.05 (0.95, 1.17)	0.31	0.65
rs10830963	92975544	11	MTNR1B	BC	G	C	rs10830963	Same	rs10830963	Same	0.32	0.95 (0.83, 1.09)	0.47	0.33	0.92 (0.75, 1.12)	0.41	0.94 (0.84, 1.05)	0.29	0.65
rs1387153	92940662	11	MTNR1B	BC	T	C					0.33	0.95 (0.84, 1.08)	0.47	0.33	1.00 (0.82, 1.23)	0.98	0.97 (0.87, 1.08)	0.54	0.75
rs1552224	72722053	11	ARAP1/CENTD2	BC	A	C	rs76550717	0.99	rs1552224	Same	0.86	1.11 (0.93, 1.31)	0.25	0.83	1.09 (0.84, 1.43)	0.52	1.10 (0.95, 1.27)	0.19	0.59
rs2237892	2818521	11	KCNQ1	BC	C	T					0.93	0.98 (0.78, 1.23)	0.87	0.96	0.76 (0.52, 1.12)	0.17	0.92 (0.75, 1.12)	0.40	0.69
rs2237897	2837316	11	KCNQ1	BC	C	T	rs2237897	Same			0.96	0.90 (0.69, 1.18)	0.44	0.97	0.78 (0.50, 1.22)	0.27	0.87 (0.69, 1.09)	0.22	0.59
<b>rs231356</b>	<b>2684113</b>	<b>11</b>	<b>KCNQ1</b>	<b>BC</b>	<b>T</b>	<b>A</b>					<b>0.28</b>	<b>1.09 (0.96, 1.24)</b>	<b>0.18</b>	<b>0.32</b>	<b>1.23 (1.02, 1.48)</b>	<b>0.03</b>	<b>1.13 (1.02, 1.26)</b>	<b>0.02</b>	<b>0.24</b>
rs231362	2670241	11	KCNQ1	BC	G	A			rs231362	Same	0.52	1.02 (0.91, 1.15)	0.76	0.52	1.11 (0.92, 1.34)	0.27	1.04 (0.95, 1.15)	0.40	0.69
rs5215	17387083	11	KCNJ11	BC	C	T	rs5219	Same	rs5215	Same	0.37	0.98 (0.87, 1.10)	0.73	0.41	1.18 (0.98, 1.41)	0.08	1.03 (0.94, 1.14)	0.51	0.75
rs1531343	65781114	12	HMGA2	IR	C	G			rs2261181	0.81	0.12	0.96 (0.80, 1.14)	0.62	0.12	0.96 (0.73, 1.26)	0.76	0.96 (0.82, 1.11)	0.55	0.75
rs7305618	120965129	12	HNF1A	BC	C	T					0.78	0.91 (0.79, 1.05)	0.20	0.79	1.06 (0.85, 1.33)	0.60	0.95 (0.85, 1.07)	0.42	0.71
rs7957197	121022883	12	HNF1A	BC	T	A			rs12427353	0.82	0.82	0.89 (0.77, 1.02)	0.10	0.16	1.17 (0.90, 1.50)	0.24	0.95 (0.84, 1.07)	0.39	0.69
rs1359790	80143021	13	SPRY2	BC	G	A	rs11616380	0.97	rs1359790	Same	0.74	1.00 (0.88, 1.14)	0.97	0.74	0.86 (0.70, 1.05)	0.13	0.95 (0.85, 1.06)	0.40	0.69
rs7961581	71269322	13	TSPAN8	BC	C	T	rs6581998	0.96	rs7955901	0.99	0.30	0.97 (0.85, 1.11)	0.67	0.27	0.96 (0.77, 1.19)	0.69	0.97 (0.87, 1.08)	0.58	0.75
rs11634397	80139880	15	ZFAND6	-	G	A			rs11634397	Same	0.65	0.99 (0.88, 1.13)	0.93	0.62	1.06 (0.87, 1.31)	0.55	1.01 (0.91, 1.13)	0.82	0.88
rs1436955	62112183	15	C2CD4B (NLF2, FAM148B)	-	C	T					0.74	0.99 (0.87, 1.13)	0.89	0.72	1.09 (0.87, 1.36)	0.44	1.02 (0.91, 1.14)	0.79	0.88
<b>rs2028299</b>	<b>89831025</b>	<b>15</b>	<b>AP3S2</b>	<b>BC</b>	<b>C</b>	<b>A</b>			<b>rs2028299</b>	<b>Same</b>	<b>0.29</b>	<b>1.18 (1.05, 1.34)</b>	<b>0.01</b>	<b>0.28</b>	<b>0.98 (0.79, 1.20)</b>	<b>0.82</b>	<b>1.12 (1.01, 1.25)</b>	<b>0.03</b>	<b>0.24</b>
rs7172432	62104190	15	C2CD4A, C2CD4B	BC	A	G			rs7163757	0.99	0.58	1.00 (0.89, 1.13)	0.97	0.55	1.15 (0.94, 1.42)	0.17	1.04 (0.94, 1.15)	0.47	0.73
rs7178572	77454848	15	HMG20A	-	G	A	rs952471	0.96	rs7178572	Same	0.71	1.01 (0.89, 1.16)	0.84	0.71	0.87 (0.71, 1.07)	0.18	0.97 (0.87, 1.08)	0.59	0.75
rs11642841	53811575	16	FTO	IR	A	C					0.39	1.08 (0.96, 1.22)	0.19	0.38	1.01 (0.82, 1.25)	0.91	1.06 (0.95, 1.17)	0.28	0.65
rs8042680	90978107	16	PRC1	BC	A	C					0.34	0.98 (0.86, 1.10)	0.69	0.70	0.89 (0.71, 1.10)	0.28	0.95 (0.86, 1.06)	0.38	0.69
<b>rs4430796</b>	<b>37738049</b>	<b>17</b>	<b>HNF1B</b>	<b>BC</b>	<b>G</b>	<b>A</b>			<b>rs4430796</b>	<b>Same</b>	<b>0.49</b>	<b>1.10 (0.98, 1.23)</b>	<b>0.12</b>	<b>0.47</b>	<b>1.17 (0.97, 1.41)</b>	<b>0.10</b>	<b>1.12 (1.01, 1.23)</b>	<b>0.03</b>	<b>0.24</b>

SNP	BP	Chr	Gene	Func	type 2 diabetes risk allele	Reference allele	Confirmation in Scott et. al., 2017 <sup>1</sup>		Confirmation in Mahajan et. al., 2014 <sup>2</sup>		NHSI			DNBC			Pooled <sup>a</sup>		<i>P</i> , FDR corrected
							Relevant SNP	R <sup>2</sup>	Relevant SNP	R <sup>2</sup>	EAF	RR (95% CI) <sup>b</sup>	P	EAF	RR (95% CI) <sup>b</sup>	P	RR (95% CI)	<i>P</i>	
rs8050136	53782363	17	FTO	IR	A	C	rs1558902	0.92	rs9936385	0.99	0.39	1.11 (0.99, 1.25)	0.08	0.39	1.01 (0.83, 1.25)	0.89	1.09 (0.98, 1.20)	0.11	0.41
rs3786897	33402102	19	PEPD	IR	A	G			rs3786897	Same	0.59	1.10 (0.98, 1.24)	0.12	0.59	1.07 (0.89, 1.30)	0.47	1.05 (0.95, 1.16)	0.34	0.69
rs8090011	7068463	19	LAMA1	-	G	C	rs7234111	0.90			0.38	1.01 (0.89, 1.14)	0.90	0.38	1.34 (1.11, 1.61)	0.00	1.09 (0.99, 1.21)	0.08	0.36
rs4812829	44360627	20	HNF4A	BC	A	G			rs4812829	Same	0.17	0.92 (0.79, 1.07)	0.29	0.21	1.03 (0.81, 1.30)	0.82	0.95 (0.83, 1.08)	0.45	0.72

<sup>a</sup>Meta-analyzed results from the two cohorts using fixed effects models weighted by inverse variance of the estimates.

<sup>b</sup>Estimated in log-binomial models adjusting for women's age.

Abbreviates: SNP – single nuclear polymorphism; Chr – chromosome; Func – functional annotation; GWAS – genome-wide association studies; EAF – effective allele frequency; RR – relative risk; CI – confidence interval; FDR – false discovery rate.




Figure S1. Relative risks and 95% confidence intervals<sup>a</sup> of type 2 diabetes associated with single nuclear polymorphism (SNP) among women who had gestational diabetes in the Nurses' Health Study II (NHSII, N=1,884) and the Danish National Birth Cohort (DNBC, N=550).

<sup>a</sup>The RRs were estimated using log-binomial models adjusting for women's age in each cohort, and then meta-analyzed using fixed effects models weighted by inverse variance of the estimates.

Table S3. Relative risks (95% confidence interval)<sup>a</sup> of type 2 diabetes associated with the genetic risk scores for beta-cell function (GRS<sub>BC</sub>) and insulin resistance (GRS<sub>IR</sub>) among women who had gestational diabetes in the Nurses' Health Study II (NHSII, N = 1,884) and the Danish National Birth Cohort (DNBC, N = 550).

		Quartiles of GRS				P-trend	Per five allele increment
		Quartile 1	Quartile 2	Quartile 3	Quartile 4		
GRS <sub>BC</sub>							
NHSII	Range	17.0-35.0	35.0-38.0	38.0-41.0	41.0-51.0		
	Case/total	120/477 (25.2)	103/502 (20.5)	93/380 (24.5)	130/525 (24.8)		
	RR (95% CI)	1.00	0.82 (0.65, 1.03)	0.99 (0.78, 1.25)	1.01 (0.82, 1.26)	0.65	1.03 (0.94, 1.14)
DNBC	Range	24.0-35.0	35.0-38.0	38.1-41.0	41.2-52.6		
	Case/total	42/165 (25.5)	45/156 (28.8)	36/119 (30.3)	32/110 (29.1)		
	RR (95% CI)	1.00	1.14 (0.80, 1.63)	1.18 (0.82, 1.72)	1.15 (0.78, 1.70)	0.43	1.07 (0.91, 1.25)
Pooled <sup>b</sup>	RR (95% CI)	1.00	0.90 (0.75, 1.10)	1.04 (0.85, 1.27)	1.04 (0.86, 1.26)	0.44	1.04 (0.96, 1.13)
GRS <sub>IR</sub>							
NHSII	Range	0.0-11.0	11.0-13.0	13.0-14.3	14.4-22.0		
	Case/total	98/543 (18.1)	86/319 (27.0)	150/563 (26.6)	112/459 (24.4)		
	RR (95% CI)	1.00	1.46 (1.14, 1.89)	1.48 (1.18, 1.85)	1.35 (1.06, 1.72)	0.01	1.23 (1.06, 1.42)
DNBC	Range	5.5-11.0	12.0-13.0	13.2-14.7	15.0-22.0		
	Case/total	47/173 (27.2)	46/162 (28.4)	19/78 (24.4)	43/137 (31.4)		
	RR (95% CI)	1.00	1.06 (0.75, 1.50)	0.90 (0.57, 1.42)	1.18 (0.84, 1.67)	0.47	1.03 (0.78, 1.35)
Pooled <sup>b</sup>	RR (95% CI)	1.00	1.31 (1.07, 1.60)	1.34 (1.10, 1.64)	1.29 (1.06, 1.58)	0.01	1.18 (1.03, 1.34)

<sup>a</sup>Estimated in log-binomial models adjusting for women's age.

<sup>b</sup>Meta-analyzed results from the two cohorts using fixed effects models weighted by inverse variance of the estimates.

**References**

1. Scott RA, Scott LJ, Mägi R, et al. An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. *Diabetes*. 2017;db161253.
2. Mahajan A, Go MJ, Zhang W, et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. In: NIH Public Access; 2014